Moors & Cabot’s Novavax NVAX Stock Holding History

Moors & Cabot’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,060	Closed	-$218K	–	948
2021 Q3	$218K	Buy	+1,060	New	+$234K	0.01%	720
2016 Q4	–	Sell	-750	Closed	-$30K	–	572
2016 Q3	$30K	Sell	750 -65	-8%	-$8.39K	0.01%	532
2016 Q2	$119K	Buy	+815	New	+$93.4K	0.02%	483

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Moors & Cabot's NVAX Position: Q4 2021 in Review

Moors & Cabot sold out of Novavax (NVAX) in Q4 2021, closing a stake of 1,060 shares — an estimated $218K sold.

Moors & Cabot first reported a position in NVAX in Q2 2016 and held it in 3 quarters. The position peaked at $218K in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

Moors & Cabot reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
Moors & Cabot sold 1,060 Novavax shares in Q4 2021, an estimated $218K.
Moors & Cabot first reported a position in Novavax in Q2 2016 and held it in 3 quarters.
Moors & Cabot's Novavax position peaked at $218K in Q3 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on Moors & Cabot's 13F filing for Q4 2021, filed 14 Feb 2022.